hope research center

nav

science-product-detail

https://doi.org/10.1016/j.ejogrb.2022.05.008

COVID-19 vaccination in pregnancy: Experience in Viet Nam

Lan N. Vuong a,b,* , Minh N. Chau b,c , Duy L. Nguyen b , Toan D. Pham b , Ben W. Mol d , Tuong M. Ho b,c

a University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Viet Nam

b HOPE Research Center, My Duc Hospital, Ho Chi Minh City, Viet Nam

c My Duc Hospital, Ho Chi Minh City, Viet Nam

d Department of Obstetrics and Gynaecology, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia

* Corresponding author at: Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy at Ho Chi Minh City, 217 Hong Bang Street, District 5, Ho Chi Minh City, Viet Nam

Abstract

Dear Editor,

Vaccination has been the most effective strategy against coronavirus 2019 disease (COVID-19). However, given the disruptive nature of the pandemic, vaccines have understandably been approved using expedited assessment processes. Studies on vaccination in pregnant women have shown no increased risk of pregnancy complications, but these had a retrospective design and/or were limited to mRNA vaccines [ Furthermore, data on the comparative impact of different vaccines in this important patient group is lacking.
Based on our experience, we compared pregnancy and neonatal outcomes in Vietnamese women vaccinated against COVID-19 with the Astra Zeneca versus Pfizer-BioNTech vaccines. Between August and November 2021, 954 pregnant women at approximately 30–31 weeks’ gestation were offered COVID-19 vaccination at My Duc Hospital, Ho Chi Minh City, Vietnam. The vaccine used (Astra Zeneca or Pfizer-BioNTech) was based availability at the time of vaccination. We prospectively followed pregnant women until their babies were delivered

KEYWORDS:

covid-19, vaccination, pregnancy

Download

Similar articles